Skip to main content
. 2020 Mar 13;8:e8286. doi: 10.7717/peerj.8286

Table 2. Variable importance generated from RF variable importance method.

Percentage increase of MSE (%)
Variables k = 1 k = 2 k = 3 k = 4 k = 5 k = 6 k = 7 k = 8 k = 9 k = 10 Average
Specific concern 14.46 10.30 10.75 12.49 15.39 14.88 4.41 11.48 14.00 18.00 12.67
Monthly income 9.81 6.56 9.77 6.41 14.03 6.59 6.11 9.39 7.21 6.39 8.23
General overuse 7.03 12.40 8.39 8.50 5.33 8.79 2.32 10.13 0.09 9.18 7.22
Marital status 7.71 6.95 4.22 15.20 2.94 11.50 9.17 6.70 −0.85 4.10 6.76
Educational level 1.94 3.64 3.71 2.67 4.79 −2.56 4.76 4.67 6.82 11.03 4.15
General harm 1.38 −0.46 7.48 2.04 0.04 8.66 9.67 5.50 −0.16 0.60 3.48
Occupational field 4.21 3.54 4.89 2.23 2.81 1.31 3.09 4.70 −2.39 7.20 3.15
Ethnicity 3.54 4.28 2.89 1.14 6.43 3.85 1.19 2.39 3.64 0.56 2.99
Specific necessity −1.56 5.91 0.92 −3.04 2.24 −3.71 6.00 0.19 −0.48 1.20 0.77
Religion 0.79 −0.28 −1.20 −0.01 2.41 −1.97 −0.37 2.03 0.91 0.39 0.27
Aids in antihypertensive medications intake −1.13 −4.02 1.08 −2.49 −3.42 5.21 0.47 2.21 −3.34 −1.37 −0.68
Total number of antihypertensive medications taken per day −4.91 −3.38 −1.27 −0.05 −1.55 −6.42 −2.54 −0.36 −3.17 −3.56 −2.72
Presence of other concomitant diseases −3.51 −3.09 −3.78 −2.46 −0.06 −5.68 −5.15 −3.58 −1.43 1.08 −2.77
Gender −3.99 −4.02 −1.93 −3.10 −2.63 −5.12 −4.13 −2.35 −1.81 −3.70 −3.28
Age −4.36 −4.24 −3.70 −3.78 −1.12 −2.88 −4.03 −6.18 −5.81 −4.23 −3.93
Duration of antihypertensive medications intake −6.05 −4.20 −5.89 −5.40 −2.18 −2.72 −3.37 −6.43 −2.74 −1.98 −4.09
Counseling for antihypertensive medications −5.61 −8.42 −5.70 −4.19 −7.62 −6.35 −8.02 −6.34 −6.20 −0.81 −5.93